Leadership
Dan Teleman
MSc, MBA - CEO
Mr. Dan Teleman has been Pharma Two B’s CEO since May 23. Dan has over 20 years of experience in the biotechnology industry. Prior to joining Pharma Two B, Dan was an Executive Partner at Israel Biotech Fund, a life science VC. Dan was Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules and a Board member of 4C Biomed, an early stage immune-oncology company developing a novel antibody. Prior to that, Dan was the CEO of Atox Bio for 12 years, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI and raised over $150M from top life science investors. Previously, Dan was the co-founder and CEO of PainReform ($PFRX), head of business development for Pharmos ($PARS) and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.
Hadas Friedman
MSc - VP Regulatory Affair & QA
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.
Shai Lankry
CPA, MBA In Finance – CFO
Shai Lankry has been our Chief Financial Officer since June 2024. Shai is a seasoned C-Level Executive with over 20 years of experience in Corporate Finance, Business Development, Investor Relations, and Executive Leadership. Before joining Pharma Two B, Shai was the CFO of Gamida Cell LTD (Nasdaq GMDA), where he played a pivotal role in advancing the lead product candidate all the way from a clinical stage to FDA approval. Shai also served as a Finance Director at West Pharmaceutical Services Inc., and as a CFO and Israeli Site Manager of Macrocure Ltd. (Nasdaq MCUR), where he was instrumental in the company’s 2014 US IPO and its 2017 acquisition by Leap Therapeutics Inc. Shai is a licensed Israeli CPA and holds an MBA in Finance from Tel Aviv University.
Sarit Zaksh
B.Sc.Pharm, MBA - Director of CMC
Sarit Zaksh brings 20 years of expertise in pharmaceuticals, specializing in drug development and manufacturing. Sarit has been at Pharma Two B since 2011 currently serving as the Director of CMC. With a background in managing a formulation lab and leading a formulation chemistry group at BioLineRx, Sarit has a proven track record of preparing new formulations for various products and implementing GMP regulations. Her earlier role as Project Manager at CTS involved full-cycle research and development of generic drugs, showcasing her comprehensive understanding of the pharmaceutical industry. Sarit holds an MBA from The Open University of Israel and a BSc in Pharmacy from The Hebrew University of Jerusalem.
Cheryl Fitzer-Attas
PhD, MBA - Head of Medical Affairs
Dr. Cheryl Fitzer-Attas has >20 years of experience in the life sciences industry, with a clinical focus on neurological indications. Today, Cheryl is President of ClinMed LLC, where she works with several companies as Senior Advisor for clinical and medical affairs. Previously, Cheryl was Senior Medical Director at Mitsubishi Tanabe Pharma America, where she established the US and global medical affairs roadmaps for a new drug-device treatment for Parkinson’s disease. Before that, Cheryl was Vice President Clinical Research at CHDI, a not-for-profit research organization dedicated to acceleration of treatments for Huntington’s disease. Previously, at Teva Pharmaceuticals Industries, Cheryl was Global Medical Director for the Parkinson’s disease drug Azilect, where she played a pivotal role in the scientific communication of Azilect’s clinical trial data, including presentation and moderation at a public FDA Advisory Committee meeting. Dr. Fitzer-Attas has a B.Sc. in biology from the Hebrew University of Jerusalem, a Ph.D. in cell biology from the Weizmann Institute of Science, an MBA in marketing from Reichmann University, and she completed post-doctoral trainings at both the Weizmann Institute of Science and the University of California, San Francisco.
Irit Zalayet
CPA, M.A. in Law - VP Finance
Ms. Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of Stem Cell Medicine.
Corinne Zollmann
PhD - CMC Consultant
Dr. Corinne Zollmann has over 30 years of experience in the pharmaceutical industry, and is currently supporting biotechnology companies by providing Chemistry, Manufacturing, and Controls (CMC) consulting services. Her prior roles include SVP of CMC at both Tamarix Pharma and at Atox Bio, where she was responsible for the CMC Modules of the Reltecimod NDA submission. Prior to that she served as Senior Director of CMC at Chiasma and spent more than 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, including as Director of the CMC Program for Small Molecules. During that time, she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, risk management, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence. Corinne holds a PhD in Electrochemistry from the Tel Aviv University, and a Master of Science degree in Analytical Chemistry and Bachelor of Science Honors in Chemistry from the University of Cape Town in South Africa.
Avigail Glass
Administration Manager
Avigail Glass serves as Pharma Two B's Administration Manager & CEO assistance as of July 2008. Prior to working at pharma Two B Avigail served as an Executive Assistant & Administration Manager at DeveloGen Israel & Intel Israel.
Dan Teleman
MSc, MBA - CEO
Dan Teleman has been Pharma Two B’s CEO since May 23 and was previously the company’s President and brings over 20 years of experience in the biotechnology industry. Dan also serves as a Board member of 4C Biomed, an early stage immune-oncology company developing a novel antibody. Prior to joining Pharma Two B, Dan was an Executive Partner at Israel Biotech Fund, a life science VC. Dan was Chairman of Tamarix Pharma, an early stage ophthalmology company developing novel anti apoptotic molecules. Prior to that, Dan was the CEO of Atox Bio, where he led the company through an NDA submission for Reltecimod, the first immunomodulator developed for NSTI. Previously, Dan was the co-founder and CEO of PainReform (Nasdaq: PRFX), head of business development for Pharmos (Nasdaq: PARS) and held marketing and sales roles at Amgen. Dan is experienced in company formation, growth and fund raising. Dan holds an MBA from Duke University, Fuqua School of Business, and an MSc in Biochemical engineering from the Ben Gurion University.
Shai Lankry
CPA, MBA In Finance – CFO
Shai Lankry has been our Chief Financial Officer since June 2024. Shai is a seasoned C-Level Executive with over 20 years of experience in Corporate Finance, Business Development, Investor Relations, and Executive Leadership. Before joining Pharma Two B, Shai was the CFO of Gamida Cell LTD (Nasdaq GMDA), where he played a pivotal role in advancing the lead product candidate all the way from a clinical stage to FDA approval. Shai also served as a Finance Director at West Pharmaceutical Services Inc., and as a CFO and Israeli Site Manager of Macrocure Ltd. (Nasdaq MCUR), where he was instrumental in the company’s 2014 US IPO and its 2017 acquisition by Leap Therapeutics Inc. Shai is a licensed Israeli CPA and holds an MBA in Finance from Tel Aviv University.
Irit Zalayet
CPA, M.A. in Law - VP Finance
Ms. Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of Stem Cell Medicine.
Hadas Friedman
MSc - VP Regulatory Affair & QA
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.
Sarit Zaksh
B.Sc.Pharm, MBA - Director of CMC
Sarit Zaksh brings 20 years of expertise in pharmaceuticals, specializing in drug development and manufacturing. Sarit has been at Pharma Two B since 2011 currently serving as the Director of CMC. With a background in managing a formulation lab and leading a formulation chemistry group at BioLineRx, Sarit has a proven track record of preparing new formulations for various products and implementing GMP regulations. Her earlier role as Project Manager at CTS involved full-cycle research and development of generic drugs, showcasing her comprehensive understanding of the pharmaceutical industry. Sarit holds an MBA from The Open University of Israel and a BSc in Pharmacy from The Hebrew University of Jerusalem.
Corinne Zollmann
PhD - CMC Consultant
Dr. Corinne Zollmann has over 30 years of experience in the pharmaceutical industry, and is currently supporting biotechnology companies by providing Chemistry, Manufacturing, and Controls (CMC) consulting services. Her prior roles include SVP of CMC at both Tamarix Pharma and at Atox Bio, where she was responsible for the CMC Modules of the Reltecimod NDA submission. Prior to that she served as Senior Director of CMC at Chiasma and spent more than 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, including as Director of the CMC Program for Small Molecules. During that time, she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer, risk management, regulatory strategy and initiatives, and professional CMC project evaluation and due diligence. Corinne holds a PhD in Electrochemistry from the Tel Aviv University, and a Master of Science degree in Analytical Chemistry and Bachelor of Science Honors in Chemistry from the University of Cape Town in South Africa.
Cheryl Fitzer-Attas
PhD, MBA - Head of Medical Affairs
Dr. Cheryl Fitzer-Attas has >20 years of experience in the life sciences industry, with a clinical focus on neurological indications. Today, Cheryl is President of ClinMed LLC, where she works with several companies as Senior Advisor for clinical and medical affairs. Previously, Cheryl was Senior Medical Director at Mitsubishi Tanabe Pharma America, where she established the US and global medical affairs roadmaps for a new drug-device treatment for Parkinson’s disease. Before that, Cheryl was Vice President Clinical Research at CHDI, a not-for-profit research organization dedicated to acceleration of treatments for Huntington’s disease. Previously, at Teva Pharmaceuticals Industries, Cheryl was Global Medical Director for the Parkinson’s disease drug Azilect, where she played a pivotal role in the scientific communication of Azilect’s clinical trial data, including presentation and moderation at a public FDA Advisory Committee meeting. Dr. Fitzer-Attas has a B.Sc. in biology from the Hebrew University of Jerusalem, a Ph.D. in cell biology from the Weizmann Institute of Science, an MBA in marketing from Reichmann University, and she completed post-doctoral trainings at both the Weizmann Institute of Science and the University of California, San Francisco.
Avigail Glass
Administration Manager
Avigail Glass serves as Pharma Two B's Administration Manager & CEO assistance as of July 2008. Prior to working at pharma Two B Avigail served as an Executive Assistant & Administration Manager at DeveloGen Israel & Intel Israel.